Physician profile
Steffani L Cotugno
NPI 1982619615
$6,555.84
in general payments reported to CMS, 2019-2025
40 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $824 · 2021: $1,490 · 2022: $1,155 · 2023: $826 · 2024: $843 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $839.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $813.63 | 2019-2025 | Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $639.86 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $627.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $451.79 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $335.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $319.51 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $316.36 | 2019-2025 | |
| Lilly USA, LLC | $271.24 | 2019-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $201.99 | 2019-2025 | Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $184.57 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $147.50 | 2021 | |
| Allergan, INC. | $143.62 | 2019-2020 | |
| Astellas Pharma US INC | $117.33 | 2022-2024 | Myrbetriq, Veozah |
| Esperion Therapeutics, INC. | $116.34 | 2020-2025 | Nexletol |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steffani Cotugno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.